Scarica l'app Stockscreener
2.90
2.03%
-0.06
Dopo l'orario di chiusura:
2.90
Precedente Chiudi:
$2.96
Aprire:
$2.93
Volume 24 ore:
407.78K
Relative Volume:
0.26
Capitalizzazione di mercato:
$76.86M
Reddito:
-
Utile/perdita netta:
$-30.26M
Rapporto P/E:
-1.4216
EPS:
-2.04
Flusso di cassa netto:
$-24.69M
1 W Prestazione:
+3.94%
1M Prestazione:
-19.44%
6M Prestazione:
+0.35%
1 anno Prestazione:
-40.08%
Intervallo 1D:
$2.80
$3.0199
Intervallo di 1 settimana:
$2.776
$3.1887
Portata 52W:
$1.11
$5.50
Annovis Bio Inc Stock (ANVS) Company Profile
Nome
Annovis Bio Inc
Settore
Industria
Telefono
484-875-3192
Indirizzo
101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA
Confronta ANVS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ANVS
Annovis Bio Inc
|
2.90 | 78.45M | 0 | -30.26M | -24.69M | -2.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Annovis Bio Inc Stock (ANVS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-10 | Downgrade | D. Boral Capital | Buy → Hold |
| 2024-10-25 | Aggiornamento | Maxim Group | Hold → Buy |
| 2023-12-29 | Iniziato | Canaccord Genuity | Buy |
| 2021-07-07 | Reiterato | Maxim Group | Buy |
Annovis Bio Inc Borsa (ANVS) Ultime notizie
Hedge Fund Bets: Will Annovis Bio Inc stock hit new highs in YEARJuly 2025 Technicals & Fast Entry and Exit Trade Plans - baoquankhu1.vn
Aug Rallies: Is Annovis Bio Inc a defensive stockQuarterly Profit Summary & Precise Swing Trade Alerts - baoquankhu1.vn
Published on: 2026-01-26 04:28:37 - baoquankhu1.vn
US Market Wrap: Can Annovis Bio Inc deliver consistent dividendsJuly 2025 Momentum & Capital Efficient Trading Techniques - baoquankhu1.vn
Movement Recap: What are the future prospects of XPeng Inc Depositary ReceiptWeekly Stock Analysis & Consistent Return Investment Signals - baoquankhu1.vn
Annovis Bio, Inc. (NYSE:ANVS) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Annovis Bio Appoints Hui Liu as Director of Biostatistics - MSN
Parkinson’s Breakthrough? New Data Shows Drug May Reverse Cognitive Decline - MSN
Value Recap: What are Hess Corporations earnings expectationsMarket Trend Report & Accurate Buy Signal Notifications - baoquankhu1.vn
Aug Outlook: Is TOMI Environmental Solutions Inc in accumulation or distribution phase2025 Technical Patterns & Weekly High Conviction Ideas - baoquankhu1.vn
Stop Loss: Is Annovis Bio Inc stock a smart retirement pickJuly 2025 Market Mood & Smart Swing Trading Alerts - baoquankhu1.vn
Can Annovis Bio Inc. stock surprise with earnings upside2025 Buyback Activity & Verified Chart Pattern Signals - Улправда
What is the fair value of Annovis Bio Inc. stock nowJuly 2025 Sector Moves & Long-Term Safe Investment Ideas - Улправда
How Annovis Bio Inc. stock reacts to oil prices2025 Biggest Moves & Daily Profit Maximizing Tips - Улправда
Will Annovis Bio Inc. stock maintain momentum in 2025Earnings Trend Report & Safe Swing Trade Setups - Улправда
Why Annovis Bio Inc. stock remains on watchlistsWeekly Gains Report & Safe Entry Zone Identification - Улправда
Will Annovis Bio Inc. stock outperform Nasdaq index2025 Trading Volume Trends & Intraday High Probability Setup Alerts - ulpravda.ru
2026 world cup match preview guide: Will Annovis Bio Inc. stock attract ESG investors2026 world cup usa national team qualification defensive leaders counter attacking group prediction tactical review - Улправда
Published on: 2026-01-06 13:56:48 - ulpravda.ru
Annovis Bio stock hits 52-week low at $4.05 amid market challenges - MSN
New trial offers extended buntanetap access for people with Parkinson’s - Parkinson's News Today
Breakout Watch: How Annovis Bio Inc stock reacts to oil pricesOptions Play & Reliable Intraday Trade Alerts - moha.gov.vn
Annovis Bio stock rating cut to hold at D. Boral Capital - MSN
History Review: Is Annovis Bio Inc stock attractive for growth ETFsJuly 2025 Update & Breakout Confirmation Alerts - moha.gov.vn
Annovis sets investor webinar as neurodegeneration pipeline reaches inflection - MSN
Annovis Bio, Inc. (NYSE:ANVS) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Published on: 2025-12-25 20:53:49 - moha.gov.vn
Annovis Launches 3-Year Parkinson’s Study to Test Long-Term Promise of Drug - MyChesCo
Annovis Sets Investor Webinar as Neurodegeneration Pipeline Reaches Inflection - MyChesCo
Inflation Data: Is Annovis Bio Inc. stock positioned for secular growthTrade Risk Summary & Verified Stock Trade Ideas - Улправда
Why analysts remain bullish on Annovis Bio Inc. stockJuly 2025 Technicals & Short-Term Swing Trade Alerts - Улправда
Is Annovis Bio Inc. stock positioned for secular growthMarket Activity Recap & AI Driven Price Predictions - Улправда
Volume Summary: Can Annovis Bio Inc. stock hold up in economic slowdownShort Setup & Technical Pattern Alert System - moha.gov.vn
What technical patterns form on Annovis Bio Inc. stock chartsTrade Entry Report & Technical Confirmation Alerts - Улправда
Why Annovis Bio Inc. stock appears on watchlistsJuly 2025 Summary & Stepwise Trade Signal Guides - DonanımHaber
Annovis Plans 36-Month Extension Study To Further Evaluate Buntanetap In Parkinson's - Nasdaq
Is Annovis Bio Inc. stock a smart buy before Fed meetingJuly 2025 Spike Watch & AI Driven Price Forecasts - DonanımHaber
Annovis Bio to launch long-term Parkinson’s drug study in January - Investing.com India
Annovis Bio to launch long-term Parkinson’s drug study in January By Investing.com - Investing.com South Africa
Annovis Bio to Launch Long-Term Open-Label Study for Buntanetap in Parkinson's Disease Patients Starting January 2026 - Quiver Quantitative
Annovis Announces Open-Label Extension Study for Parkinson's Disease Patients - GlobeNewswire
Annovis Bio Advances Long-Term Buntanetap Safety Study in Parkinson’s Disease - TipRanks
Will Annovis Bio Inc. stock attract ESG investorsTrade Performance Summary & Real-Time Stock Entry Alerts - Улправда
Annovis to Host Corporate Update Webinar on January 28, 2026 - GlobeNewswire
About Us | Cabling Installation & MaintenanceAnnovis to Host Corporate Update Webinar on January 28, 2026 - FinancialContent
Alzheimer's drug hunt learns from cancer fight's multi-target playbook - Reuters
Keeping Neurodegeneration Top Of Mind: Is Annovis Bio's Pipeline Progress Enough? - RTTNews
ANVS SEC FilingsAnnovis Bio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Annovis Bio director Hoffman buys $193,794 in shares By Investing.com - Investing.com UK
Annovis Bio (NYSE:ANVS) Director Purchases $193,950.00 in Stock - MarketBeat
Annovis Bio Inc Azioni (ANVS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.09%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):